Diovan (valsartan) is a prescription drug taken to treat high blood pressure and lower certain cardiovascular (heart and blood vessel) risks. Diovan can cause side effects that range from mild to ...

The approval was based on data from 3 clinical studies that assessed the antihypertensive effect of valsartan in 290 children 1 to less than 6 years of age. The Food and Drug Administration (FDA) has ...

Generic Diovan is coming. The Wall Street Journal reports that generics drugmaker Ranbaxy has scored an FDA approval to manufacture an off-brand version of the blood pressure medication. The drug will ...

WASHINGTON/MUMBAI (Reuters) - Ranbaxy Laboratories Ltd (RANB.NS) has received approval from the U.S. Food and Drug Administration (FDA) to launch a cheaper copy of Novartis AG's blood pressure pill ...

Pfizer's ($PFE) success with co-pay coupons has encouraged other blockbuster-losing Big Pharmas to follow suit. Have the others been able to replicate Pfizer's ...

Although the patent on valsartan (Diovan, Novartis) expired last Friday, a generic version of the popular antihypertensive drug has yet to make it to market. By contrast, a generic version of Diovan ...

EAST HANOVER, N.J., Aug. 4 /PRNewswire/ -- The US Food and Drug Administration (FDA) has approved two single-pill combination medications, Diovan HCT(R) (valsartan and hydrochlorothiazide) and Exforge ...

Ranbaxy’s export woes may be hurting its own sales, but the Indian generics firm is actually making life easier for Novartis. Ranbaxy currently holds exclusive rights to sell the generic version of ...

A few years ago India’s Alkem Laboratories was in the hot seat with the FDA, having had several plants cited by inspectors. Today it is in the driver’s seat after the agency approved its new generic ...

Diovan HCT is used for the treatment of high blood pressure (:HBP). According to IMS Health, Diovan HCT (80/12.5 mg, 160/12.5 mg, 160/25 mg, 320/12.5 mg and 320/25 mg tablets), generated US revenues ...

This latest evaluation is part of a giant clinical trials program for Diovan that Novartis is conducting under a strategy to widen the drug’s market opportunity as well as extend its patent armour, ...